Cargando…
Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria
BACKGROUND: Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpretation: lack of established IC(50) values indicati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186475/ https://www.ncbi.nlm.nih.gov/pubmed/24299049 http://dx.doi.org/10.1111/irv.12215 |
_version_ | 1782338069447311360 |
---|---|
author | Okomo-Adhiambo, Margaret Nguyen, Ha T Abd Elal, Anwar Sleeman, Katrina Fry, Alicia M Gubareva, Larisa V |
author_facet | Okomo-Adhiambo, Margaret Nguyen, Ha T Abd Elal, Anwar Sleeman, Katrina Fry, Alicia M Gubareva, Larisa V |
author_sort | Okomo-Adhiambo, Margaret |
collection | PubMed |
description | BACKGROUND: Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpretation: lack of established IC(50) values indicative of clinically relevant resistance and insufficient harmonization of NI testing methodologies among surveillance laboratories. In 2012, the WHO working group on influenza antiviral susceptibility (WHO-AVWG) developed criteria to facilitate consistent interpretation and reporting of NI assay data. METHODS: The WHO-AVWG classification criteria were applied in interpreting NI assay data for two FDA-licensed NAIs, oseltamivir and zanamivir, for viruses collected in the United States during the 2011–2012 winter season. RESULTS: All A (H1N1)pdm09 viruses (n = 449) exhibited normal inhibition by oseltamivir and zanamivir, with the exception of eight viruses (1·8%) with highly reduced inhibition by oseltamivir, which carried the H275Y marker of oseltamivir resistance. A (H3N2) viruses (n = 978) exhibited normal inhibition by both NAIs, except for one virus with highly reduced inhibition by zanamivir due to the cell culture-selected NA change, Q136K. Type B viruses (n = 343) exhibited normal inhibition by both drugs, except for an isolate with reduced inhibition by both NAIs that had the cell culture-selected A200T substitution. CONCLUSIONS: WHO-AVWG classification criteria allowed the detection of viruses carrying the established oseltamivir resistance marker, as well as viruses whose susceptibility was altered during propagation. These criteria were consistent with statistical-based criteria for detecting outliers and will be useful in harmonizing NI assay data among surveillance laboratories worldwide and in establishing laboratory correlates of clinically relevant resistance. |
format | Online Article Text |
id | pubmed-4186475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-41864752014-10-29 Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria Okomo-Adhiambo, Margaret Nguyen, Ha T Abd Elal, Anwar Sleeman, Katrina Fry, Alicia M Gubareva, Larisa V Influenza Other Respir Viruses Original Articles BACKGROUND: Assessing susceptibility of influenza viruses to neuraminidase (NA) inhibitors (NAIs) is primarily done in NA inhibition (NI) assays, supplemented by NA sequence analysis. However, two factors present challenges for NI assay data interpretation: lack of established IC(50) values indicative of clinically relevant resistance and insufficient harmonization of NI testing methodologies among surveillance laboratories. In 2012, the WHO working group on influenza antiviral susceptibility (WHO-AVWG) developed criteria to facilitate consistent interpretation and reporting of NI assay data. METHODS: The WHO-AVWG classification criteria were applied in interpreting NI assay data for two FDA-licensed NAIs, oseltamivir and zanamivir, for viruses collected in the United States during the 2011–2012 winter season. RESULTS: All A (H1N1)pdm09 viruses (n = 449) exhibited normal inhibition by oseltamivir and zanamivir, with the exception of eight viruses (1·8%) with highly reduced inhibition by oseltamivir, which carried the H275Y marker of oseltamivir resistance. A (H3N2) viruses (n = 978) exhibited normal inhibition by both NAIs, except for one virus with highly reduced inhibition by zanamivir due to the cell culture-selected NA change, Q136K. Type B viruses (n = 343) exhibited normal inhibition by both drugs, except for an isolate with reduced inhibition by both NAIs that had the cell culture-selected A200T substitution. CONCLUSIONS: WHO-AVWG classification criteria allowed the detection of viruses carrying the established oseltamivir resistance marker, as well as viruses whose susceptibility was altered during propagation. These criteria were consistent with statistical-based criteria for detecting outliers and will be useful in harmonizing NI assay data among surveillance laboratories worldwide and in establishing laboratory correlates of clinically relevant resistance. Blackwell Publishing Ltd 2014-03 2013-12-02 /pmc/articles/PMC4186475/ /pubmed/24299049 http://dx.doi.org/10.1111/irv.12215 Text en © 2013 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Okomo-Adhiambo, Margaret Nguyen, Ha T Abd Elal, Anwar Sleeman, Katrina Fry, Alicia M Gubareva, Larisa V Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria |
title | Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria |
title_full | Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria |
title_fullStr | Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria |
title_full_unstemmed | Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria |
title_short | Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria |
title_sort | drug susceptibility surveillance of influenza viruses circulating in the united states in 2011-2012: application of the who antiviral working group criteria |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186475/ https://www.ncbi.nlm.nih.gov/pubmed/24299049 http://dx.doi.org/10.1111/irv.12215 |
work_keys_str_mv | AT okomoadhiambomargaret drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria AT nguyenhat drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria AT abdelalanwar drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria AT sleemankatrina drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria AT fryaliciam drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria AT gubarevalarisav drugsusceptibilitysurveillanceofinfluenzavirusescirculatingintheunitedstatesin20112012applicationofthewhoantiviralworkinggroupcriteria |